article · Discover Molecules
As of right now, more than 776 million people have contracted the COVID-19-causing SARS-CoV-2 virus, which has also resulted in over 7 million deaths. A dysregulated host's innate immune response to the virus exacerbates clinical outcomes and leads to cytokine storm. Developing a drug targeting the multiple aspects of the SARS-CoV-2 virus-host cell interactions is essential for effective treatment. The 75 amino acid-long SARS-CoV-2 envelope (2E) protein is a small structural transmembrane protein that plays a crucial role in the viral life cycle and pathogenesis. Mappain is a plant-derived stilbene from Macaranga species that previously demonstrated antiviral potential against enteroviruses in tissue culture. This study aims to assess the inhibitory potential of Mappain against SARS-CoV-2 key proteins and induced hyperinflammation using computational and in-vitro approaches. Autodock Vina was used to evaluate mappain interaction with SARS- CoV-2 antiviral targets including Spike, Envelope, Membrane, 3CLPro, PLpro, Nucleocapsid N and C termini, RdRP, and host receptors—TLR2, TLR3, TLR7, and TLR8. Afterwards, mappain was subjected to in-vitro bioassay testing using inhibition 2E-induced cytokines (IL-6 and TNF-α) in human peripheral blood mononuclear cells, measured by ELISA; Amantadine as control. KEGG pathway enrichment analysis was further performed using network pharmacology to elucidate the mechanism. Mappain demonstrated a high binding score with all the targets, especially with the envelope protein (− 9.6 kcal/mol) and TLR2 (− 9.7 kcal/mol) compared to Amantadine (− 6.1 kcal/mol and − 5.5 kcal/mol, respectively). Mappain also significantly reduced the expression of 2E-induced Interleukin 6 (p ≤ 0.001) and tumour necrosis factor-alpha (p ≤ 0.01) in the PBMCs, when compared to Amantadine HCl. The KEGG Pathway enrichment analysis supports the anti-inflammatory potential of mappain in the virus-induced cytokine storm by specifically targeting TLR signalling and COVID-19 pathways.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1007/s44345-024-00006-4
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.